Tanaka K, Ogawa N, Asanuma M, Hirata H, Kondo Y, Nakayama N, Mori A
Department of Neuroscience, Okayama University Medical School, Japan.
Arch Int Pharmacodyn Ther. 1993 May-Jun;323:85-96.
The effects of a new acetylcholinesterase inhibitor, ENA-713, on ischemia-induced changes in acetylcholine, monoamines, and their metabolites, were studied in the gerbil. ENA-713 (0.2 mg/kg) or saline was administered intraperitoneally to gerbils 30 min before induction of cerebral ischemia by bilateral carotid occlusion. Pretreatment with ENA-713 mitigated the ischemia-induced abnormalities of the cholinergic, dopaminergic and serotoninergic systems in the gerbil brain, although it had virtually no effect on acetylcholine, monoamines, or their metabolites in any region of the normal gerbil brain. These findings suggest that ENA-713 has beneficial effects against ischemia-induced cerebral disorders. Thus, ENA-713 seems to be promising as a preventive or therapeutic agent for cerebrovascular dementia due to cerebral ischemia and might be useful for the treatment of Alzheimer-type dementia which is associated with multiple neurotransmitter abnormalities in the brain.
在沙鼠身上研究了一种新型乙酰胆碱酯酶抑制剂ENA - 713对缺血诱导的乙酰胆碱、单胺及其代谢产物变化的影响。在通过双侧颈动脉闭塞诱导脑缺血前30分钟，向沙鼠腹腔注射ENA - 713（0.2mg/kg）或生理盐水。ENA - 713预处理减轻了沙鼠脑中缺血诱导的胆碱能、多巴胺能和5-羟色胺能系统异常，尽管它对正常沙鼠脑的任何区域的乙酰胆碱、单胺或其代谢产物几乎没有影响。这些发现表明ENA - 713对缺血诱导的脑部疾病具有有益作用。因此，ENA - 713作为一种针对脑缺血所致脑血管性痴呆的预防或治疗药物似乎很有前景，并且可能对治疗与脑内多种神经递质异常相关的阿尔茨海默型痴呆有用。
